Should You Buy Jazz Pharmaceuticals plc Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Jazz Pharmaceuticals plc (JAZZ) is rated as a strong fundamental performer with a QOC score of 7.6/10. Trading at $240.83, our valuation engine evaluates whether the market price reflects the company's underlying earnings power.
The short answer: 4 of 6 CirclFi valuation models project upside for Jazz Pharmaceuticals plc (JAZZ) at $240.83 — the model consensus leans bullish, with a Quality Score of 7.6/10 and Value-Trap risk of 6/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Jazz Pharmaceuticals plc (JAZZ) in 2026?
What Is the Bull Case vs the Bear Case for Jazz Pharmaceuticals plc (JAZZ)?
| Bull case — $739.79 target (+207.2%) | Bear case — $123.51 target (-48.7%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Jazz Pharmaceuticals plc's score of 7.6/10 reflects durable competitive advantages that should sustain earnings power through market cycles. | According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model sees the stock as overvalued with a fair value of $123.51 (-48.7%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the stock shows multi-model upside with a median implied return of +45.4% across 4 bullish models from the current price of $240.83. | According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +255.9% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. |
| According to the CirclFi Deep Alpha Valuation Engine, the Bayesian DCF model targets a fair value of $739.79 (+207.2%), anchoring the bull case with a methodology that incorporates probability-weighted cash flow scenarios. | Industry headwind: dilutive capital raises represents a meaningful risk for Jazz Pharmaceuticals plc and its Biotechnology peers. |
| Industry tailwind: platform technology validation could provide meaningful support for Jazz Pharmaceuticals plc's revenue and margin trajectory in the Biotechnology space. |
How Does JAZZ Compare to Its Biotechnology Peers?
Valuation data pages: ARWR · BDTX · GYRE · SPRO · NVAX · TWST · FTRE · NGNE · TOVX · EXEL · INCY
Which Other Stocks Score Like JAZZ on Quality?
Closest companies to JAZZ’s Quality of Company score of 7.6/10, across all industries.
- CNH — CNH Industrial N.V. (QOC 7.6) · analysis
- ATLC — Atlanticus Holdings Corporation (QOC 7.6) · analysis
- LIND — Lindblad Expeditions Holdings, Inc. (QOC 7.6) · analysis
- ACI — Albertsons Companies, Inc. (QOC 7.6) · analysis
- BBT — Beacon Financial Corporation (QOC 7.6) · analysis
- SGHC — Super Group (SGHC) Limited (QOC 7.6) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Biotechnology Screens Does JAZZ Appear In?
So Is Jazz Pharmaceuticals plc (JAZZ) Worth Buying in 2026?
The balance of evidence tilts cautiously positive for Jazz Pharmaceuticals plc at $240.83. 4 of 6 models support upside to $350.05, backed by a 7.6/10 quality foundation. This is a "lean into, not load up on" setup in our framework.
These are quantitative model outputs, not investment recommendations. Jazz Pharmaceuticals plc's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About JAZZ Stock?
Should I buy JAZZ stock right now?
Based on CirclFi's multi-model analysis, 4 of 6 models see upside for JAZZ at $240.83. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 7.6/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Jazz Pharmaceuticals plc?
Key risks include: limited model coverage (6/13 active), reducing analytical confidence; wide model disagreement (499% spread), signaling high uncertainty; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does JAZZ compare to its competitors?
Among Biotechnology peers, JAZZ holds a Quality Score of 7.6/10. Comparable companies include ARWR (QOC 7.6), BDTX (QOC 7.5), GYRE (QOC 7.6). The relative ranking helps investors identify whether JAZZ offers better fundamental quality than alternatives in the same sector.
Is JAZZ a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. JAZZ's Quality Score of 7.6/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy JAZZ at?
CirclFi does not provide target buy prices or price alerts. However, our 6 active models produce fair value estimates ranging from $123.51 to $739.79. At $240.83, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for JAZZ.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad